A Phase 1, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Two Different Intranasal Formulations of MSP-2017 in Healthy Adult Male Subjects.

Trial Profile

A Phase 1, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Two Different Intranasal Formulations of MSP-2017 in Healthy Adult Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Etripamil (Primary)
  • Indications Arrhythmias; Paroxysmal supraventricular tachycardia
  • Focus Adverse reactions
  • Sponsors Milestone Pharmaceuticals
  • Most Recent Events

    • 24 Nov 2014 Results published in a Milestone Pharmaceuticals media release.
    • 24 Nov 2014 Status changed from recruiting to completed, according to a Milestone Pharmaceuticals media release.
    • 24 Nov 2014 One of the two trial formulations of MSP 2017 has been selected for a phase II proof-of-concept study, according to a Milestone Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top